Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab monotherapy or tocilizumab plus methotrexate versus methotrexate in early moderate to severe rheumatoid arthritis
2009-012759-12Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab monotherapy, Tocilizumab plus methotrexate and Methotrexate monotherapy (3 arms). Primary endpoints: DAS28 remission response at Week 24 and Prevention of structural joint damage over 12 months and maintenance at 24 months. Started Aug 2009; status: completed.
02
Drugs
tocilizumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-012759-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012759-12.